| Hans-Günter Meyer-Thompson | Buprenorphin
Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study.
Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study.
Hard B, DeSilva M.
Pilot Feasibility Stud. 2023 Jul 4;9(1):113. doi: 10.1186/s40814-023-01348-5. PMID: 37403145; PMCID: PMC10318660.